Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts. Show more

Location: 830 Winter Street, Waltham, MA, 02451, United States | Website: https://www.q32bio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

40.85M

52 Wk Range

$1.34 - $27.61

Previous Close

$3.62

Open

$3.56

Volume

580,915

Day Range

$3.21 - $3.66

Enterprise Value

8.836M

Cash

49.04M

Avg Qtr Burn

-9.698M

Insider Ownership

6.48%

Institutional Own.

64.41%

Qtr Updated

09/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bempikibart (ADX-914) Details Atopic dermatitis, Skin disease/disorder	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bempikibart (ADX-914) Details Alopecia areata	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADX-097 Details Renal disease, Lupus nephritis, IgA nephropathy, C3 Glomerulopathy	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADX-097 Details Renal disease, ANCA-Associated Vasculitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.